RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

Makoto Nishio, Kazuto Nishio, Martin Reck, Edward B Garon, Fumio Imamura, Tomoya Kawaguchi, Hiroyuki Yamaguchi, Satoshi Ikeda, Katsuya Hirano, Carla Visseren-Grul, Matteo Ceccarelli, Sameera R Wijayawardana, Annamaria Zimmermann, Tomoko Matsui, Sotaro Enatsu, Kazuhiko Nakagawa, Makoto Nishio, Kazuto Nishio, Martin Reck, Edward B Garon, Fumio Imamura, Tomoya Kawaguchi, Hiroyuki Yamaguchi, Satoshi Ikeda, Katsuya Hirano, Carla Visseren-Grul, Matteo Ceccarelli, Sameera R Wijayawardana, Annamaria Zimmermann, Tomoko Matsui, Sotaro Enatsu, Kazuhiko Nakagawa

Abstract

Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period, single-arm, exploratory study of RAM plus gefitinib (GEF; period 1) and RAM plus osimertinib (period 2) in East Asia (NCT02411448).

Methods: Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated EGFR-mutated metastatic NSCLC. Period 2 evaluated RAM plus osimertinib (80 mg/d) in patients with disease progression who acquired T790M mutation in period 1. Exploratory end points included 1-year PFS rate (primary), other efficacy parameters, safety, and biomarker analyses of plasma (baseline, on-treatment, follow-up) using next-generation sequencing.

Results: From December 2017 to August 2018, a total of 82 patients were enrolled and started treatment (period 1, RAM + GEF). The 1-year PFS rate was 62.9% (95% confidence interval: 50.3-73.1). Treatment-emergent adverse events of grade three or higher were reported with RAM plus GEF in 60 of 82 patients (73.2%; five patients [6.1%] grade four). There were two deaths owing to adverse events that occurred (acute cardiac failure, congestive cardiac failure). T790M rate at disease progression in plasma was 81.0% (13 of 16 patients).

Conclusions: RELAY+ was found to have a favorable benefit-risk profile for RAM plus GEF in first-line treatment of East Asian patients with EGFR-mutated NSCLC.

Keywords: East Asia; Japan; Plasma biopsy; Treatment outcome; Vascular endothelial growth factor receptor-2.

© 2022 The Authors.

Figures

Figure 1
Figure 1
RELAY+ exploratory open-label cohort: (A) study design and (B) patient disposition. aThe exploratory cohort included patients enrolled in Japan, South Korea, and Taiwan. bDeath due to adverse event. One patient died due to acute cardiac failure and one patient died due to congestive cardiac failure. Both events were considered related to the study treatment. Data cutoff date: November 25, 2020. GEF, gefitinib; ITT, intent-to-treat; OSI, osimertinib; q2w, once every 2 weeks; RAM, ramucirumab.
Figure 2
Figure 2
Swimmer plot of treatment sequence for (A) Japanese patients and (B) non-Japanese patients (RELAY+ period 1 ITT population). EGFR-Other = gefitinib, erlotinib, or afatinib as postdiscontinuation treatment; Chemo-ICI = chemotherapy/immunotherapy/PD-(L)1 inhibitor; EGFR-OSI = osimertinib; P2-OSI = osimertinib received in period 2; P2-RAM = ramucirumab received in period 2; VEGF-RAM = ramucirumab as postdiscontinuation treatment. Chemo, chemotherapy; GEF, gefitinib; ICI, immune checkpoint inhibitor; ITT, intent-to-treat; OSI, osimertinib; P2, period 2; PD, progressive disease; PD-(L)1, programmed death-(ligand) 1; RAM, ramucirumab; VEGF, vascular endothelial growth factor.
Figure 3
Figure 3
Kaplan-Meier plot of investigator-assessed 1-year PFS rate (period 1 ITT population). CI, confidence interval; ex19del, in-frame deletions of exon 19; ex21.L858R, L858R point mutation in exon 21; GEF, gefitinib; ITT, intent-to-treat; PFS, progression-free survival; RAM, ramucirumab.

References

    1. World Health Organization. Globocan 2020 Cancer fact sheets: Eastern Asia.
    1. Shi Y., Au J.S., Thongprasert S., et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) J Thorac Oncol. 2014;9:154–162.
    1. Zhang Y.L., Yuan J.Q., Wang K.F., et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–78993.
    1. Hsu W.H., Yang J.C., Mok T.S., Loong H.H. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3–i9.
    1. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346.
    1. Lung Cancer Practice Guidelines 2020 Edition. II Non-small cell lung cancer (NSCLC). Section 7.
    1. Ninomiya K., Teraoka S., Zenke Y., et al. Japanese Lung Cancer Society Guidelines for stage IV NSCLC with EGFR mutations. JTO Clin Res Rep. 2021;2
    1. Wu Y.L., Planchard D., Lu S., et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:171–210.
    1. Mayo-de-Las-Casas C., Jordana-Ariza N., Garzón-Ibañez M., et al. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. Ann Oncol. 2017;28:2248–2255.
    1. Yu H.A., Arcila M.E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.
    1. Akamatsu H., Ninomiya K., Kenmotsu H., et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019;24:731–770.
    1. Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:504–535.
    1. Naumov G.N., Nilsson M.B., Cascone T., et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15:3484–3494.
    1. Seto T., Kato T., Nishio M., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236–1244.
    1. Saito H., Fukuhara T., Furuya N., et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–635.
    1. Zhou Q., Wu Y.L., Cheng Y., et al. CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC [abstract] Ann Oncol. 2019;30:v603.
    1. Nakagawa K., Garon E.B., Seto T., et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:1655–1669.
    1. Nishio K., Seto T., Nishio M., et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated metastatic EGFR-mutated NSCLC: RELAY Japanese subset. JTO Clin Res Rep. 2021;2
    1. Nishio M., Seto T., Reck M., et al. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. Cancer Sci. 2020;111:4510–4525.
    1. Kohsaka S., Nagano M., Ueno T., et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med. 2017;9
    1. Nakagawa K., Tamura T., Negoro S., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003;14:922–930.
    1. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267–3279.
    1. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–181.
    1. Schuette W., Schirmacher P., Eberhardt W.E., et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomarkers Prev. 2015;24:1254–1261.
    1. Inoue A., Yoshida K., Morita S., et al. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol. 2016;46:462–467.
    1. Zhang W., Wei Y., Yu D., Xu J., Peng J. Gefitinib provides similar effectiveness and improved safety than erlotinib for East Asian populations with advanced non-small cell lung cancer: a meta-analysis. BMC Cancer. 2018;18:780.
    1. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
    1. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128.
    1. Wu Y.L., Cheng Y., Zhou X., et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–1466.
    1. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
    1. Wu Y.L., Zhou C., Liam C.K., et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26:1883–1889.
    1. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742.
    1. Park K., Tan E.H., O’Byrne K., et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589.
    1. Ichihara E., Hotta K., Nogami N., et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol. 2015;10:486–491.
    1. Ramalingam S.S., Vansteenkiste J., Planchard D., et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
    1. Cho B.C., Chewaskulyong B., Lee K.H., et al. Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol. 2019;14:99–106.
    1. Mok T.S., Cheng Y., Zhou X., et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36:2244–2250.
    1. Fabbrocini G., Panariello L., Caro G., Cacciapuoti S. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Skin Appendage Disord. 2015;1:31–37.
    1. Kiyohara Y., Yamazaki N., Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69:463–472.
    1. Hayman S.R., Leung N., Grande J.P., Garovic V.D. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14:285–294.
    1. Takeda M., Okamoto I., Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015;88:74–79.
    1. Yoneda K.Y., Hardin K.A., Gandara D.R., Shelton D.K. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer. 2006;8(suppl 1):S31–S35.
    1. Takano T., Fukui T., Ohe Y., et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589–5595.
    1. Seto T., Nogami N., Yamamoto N., et al. Real-world EGFR T790M testing in advanced non-small-cell lung cancer: a prospective observational study in Japan. Oncol Ther. 2018;6:203–215.
    1. Wu Z., Yang Z., Dai Y., Zhu Q., Chen L.A. Update on liquid biopsy in clinical management of non-small cell lung cancer. Onco Targets Ther. 2019;12:5097–5109.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren